Can a withdrawn myeloma drug make a comeback with a gentler schedule?

NCT ID NCT05874193

Not yet recruiting Disease control Sponsor: Cristiana Costa Chase, DO Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, but some patients still benefited. The trial will enroll 33 heavily pretreated patients, including elderly and frail individuals, to see if the every-6-week schedule is feasible and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (a targeted antibody-drug conjugate) plus dexamethasone (a steroid)
What this could lead to: If successful, this could show that giving belantamab mafodotin every 6 weeks in community clinics is safe and effective, offering a more convenient option for patients with advanced multiple myeloma.
What could go wrong: This is a small, early-phase trial (33 people) and the drug was previously withdrawn from the market after a confirmatory study failed. It is unclear if the every-6-week schedule will work as well as the standard every-3-week schedule.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Johnston Cancer Center

Smithfield, North Carolina, 27577, United States
Johnston Hematology and Oncology of Clayton

Clayton, North Carolina, 27570, United States
Maria Parham Hospital

Henderson, North Carolina, 27536, United States
Scotland Health Care System

Laurinburg, North Carolina, 28352, United States
UNC Health Southeastern

Lumberton, North Carolina, 28358, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.